Mr Altmeyer succeeds interim president and CEO of Otsuka America Pharmaceutical, Dean Haubrich, who has been leading the company since August 1, 2008 and has been named chairman of the Otsuka America Pharmaceutical board.
Mr Altmeyer joins Otsuka from Bristol-Myers Squibb Co, where he spent 16 years successfully promoting and developing neuroscience, oncology, and metabolic/cardiovascular brands.
Dean Haubrich, chairman of board of directors at Otsuka America Pharmaceutical, said: “As Otsuka continues to develop strong people, products, and partnerships, I am confident that Mark’s leadership will help propel the global Otsuka organization to become a top tier global pharmaceutical company.”